Global Leader in Holistic and Integrative Medicine to Assist Field Trip with Enhancing Treatments and Future Expansion Plans
TORONTO, Oct. 8, 2020 — Field Trip Health Ltd. (CSE: FTRP) (“Field Trip”), the global leader in the development and delivery of technology-enabled psychedelic therapies, today announced the addition of Andrew Weil, M.D., world-renowned leader and pioneer in the field of integrative medicine, to its medical advisory board. In this role, Dr. Weil will provide Field Trip with medical advice and expertise on healing-oriented approaches to healthcare, as well as guidance on extending the influence and reach of psychedelic therapies.
Combining a Harvard education and a lifetime of practicing natural and preventive medicine, Dr. Weil is the founder and director of the Andrew Weil Center for Integrative Medicine at the University of Arizona, where he also holds the Lovell-Jones Endowed Chair in Integrative Rheumatology, and is Clinical Professor of Medicine and Professor of Public Health. The Center is leading the effort to develop a comprehensive curriculum in integrative medicine. Graduates serve as directors of integrative medicine programs throughout the United States, and through its fellowship, the Center is now training doctors and nurse practitioners around the world. Dr. Weill is one of the most respected physicians in the world and has decades of personal and professional experience with the healing nature of psychedelics.
“I am extremely pleased to be joining the medical advisory board at Field Trip,” said Dr. Weil. “Field Trip’s mission, as well as the energy, enthusiasm and commitment to thoughtful, modern and responsible approaches to psychedelic medicine that the team at Field Trip is pursuing are remarkable. They are consistent with, not only my approach to the practice of medicine, but how I see modern approaches to medicine evolving. More and more, we are seeing that the mind plays an essential role in medicine and healing and Field Trip is at the forefront of revolutionizing mental, emotional and behavioural health through psychedelic therapies.”
“It is an honour and privilege to welcome Dr. Weil to our medical advisory board. Andy is widely recognized as one of the forefathers of modern integrative medicine. He is internationally recognized for his thought leadership in medicine, healthcare and the therapeutic applications of once-stigmatized drugs and medicines. Andy’s experience working with psychedelics is unparalleled, and helped form the basis for his integrated medical philosophy. His unique insights will provide critical guidance as we grow our footprint in and cultivate our treatment framework from start to post-experience integration for the people seeking treatment in our centers,” said Ronan Levy, Field Trip’s Executive Chairman.
Field Trip recently announced the opening of its Field Trip Health centers in New York City, Los Angeles, and Toronto, which are providing best-in-class, technology-enabled psychedelic-assisted psychotherapy.
About Field Trip Health Ltd.
Field Trip is the global leader in the development and delivery of psychedelic therapies. With Field Trip Discovery leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics, Field Trip Health hubs for psychedelic therapies opening across North America, and Field Trip Digital building the digital and technological tools to support psychedelic experiences and consciousness expansion, we help people, from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world.
Follow us on Twitter and Instagram: @fieldtriphealth
To receive company updates about Field Trip and to be added to the email distribution list please sign up here.
Cautionary Note Regarding Forward Looking Information
This release includes forward-looking information within the meaning of Canadian securities laws regarding Field Trip and its business, which may include, but are not limited to, statements with respect to the listing of the common shares of Field Trip on the Canadian Securities Exchange, and the timing of such events. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip, and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the COVID-19 epidemic, the medical clinic industry, market conditions, economic factors, management’s ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
The CSE has neither approved nor disapproved the contents of this news release.
SOURCE Field Trip Health Ltd.